 -- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from long-term extension study in POMC deficiency obesity showed durable weight loss and reductions in hunger at up to three years on therapy -- -- Setmelanotide was generally well tolerated -- BOSTON, Nov. 04, 2020 GLOBE NEWSWIRE -- Rhythm Pharmaceuticals, Inc. Nasdaq:RYTM, a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced new clinical data for setmelanotide, its investigational melanocortin-4 receptor MC4R agonist, being presented at The Obesity Societys ObesityWeek 2020, held virtually from November 2-6, 2020. 